Your session is about to expire
← Back to Search
CED with MTX110 for Brain Cancer
Study Summary
This trial is testing a new way to give drugs to children with brain tumors. The drugs are put directly into the tumor, which may reduce side effects for the patient.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 7 Patients • NCT03566199Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who meets the criteria for enrollment in this research project?
"To partake in this clinical trial, enrollees should have diffuse intrinsic pontine glioma and inhabit the age range of 3 to 18. The total number of participants is expected to reach 9 individuals."
What are the chief aims of this research?
"This clinical trial will be conducted over a fortnight and it's primary objective is to evaluate Adverse Events Incidence. Secondary goals include ascertaining the Overall Survival (OS) rate, Time to Tumor Progression/Recurrence (PFS), and Steady State Volume of Drug Distribution – all determined by follow-up with participants per 3-6 months or magnetic resonance imaging scans."
Are there any openings left for enrollment in this clinical trial?
"According to data available on clinicaltrials.gov, this study is currently seeking applicants; it was initially posted in March of 2020 and recently revised in early March 2022."
What is the upper limit of participants for this clinical trial?
"Indeed, the records on clinicaltrials.gov demonstrate that this medical trial is recruiting right now. It was first posted on March 10th 2020 and revised most recently on March 8th 2022. For its success, 9 participants need to be enlisted from one site."
Does the research study allow participants of under 65 years to take part?
"This scientific research requires participants to fall between the ages of 3 and 18. Data collected thus far shows that 143 studies include individuals younger than 18, while 247 include seniors above 65 years old."
What potential risks are associated with Convection-Enhanced Delivery (CED) for humans?
"Our evaluation concluded that Convection-Enhanced Delivery (CED) is cautiously safe, scoring a 1 on our scale. This low score indicates limited data regarding the efficacy and safety of CED."
Has Convection-Enhanced Delivery (CED) been studied in past clinical trials?
"Currently, 10 CED trials are active with none of them at the Phase 3 stage. Birmingham, Alabama is one hub for such research; however, 26 other locations across America offer clinical studies related to Convection-Enhanced Delivery (CED)."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Columbia University Irving Medical Center: < 48 hours
Share this study with friends
Copy Link
Messenger